The Wiley Protocol is Not Recommended for Hormone Therapy
The Wiley Protocol should not be used for hormone therapy, as it represents an unregulated, ethically problematic approach that fails to meet established standards for patient safety and informed consent, and is not endorsed by any major medical society or guideline. 1
What is the Wiley Protocol?
The Wiley Protocol is a proprietary hormone regimen that uses compounded bioidentical hormones (estradiol, progesterone, DHEA, and testosterone) in transdermal cream formulations, marketed directly to consumers through books, popular press, and the internet 1. While proponents claim it provides "standardized" dosing 2, this protocol operates outside the framework of evidence-based medicine and regulatory oversight.
Critical Ethical and Safety Concerns
Regulatory and Research Ethics Violations
The protocol has been identified as unregulated research involving potentially unsafe doses applied to unselected populations of women 1. Specific violations include:
- Lack of informed consent regarding actual risks
- Absence of data safety monitoring
- No standardized methodology for outcome assessment
- Inadequate investigator expertise and training requirements
- Conflicts of interest related to financial incentives and patient recruitment 1
Clinical Ethics Breaches
- Incomplete disclosure of risks to patients
- Coercive influences in marketing materials
- Misinformation about study goals and safety
- Inadequate standards of proficiency among participating providers 1
Evidence-Based Alternatives
Guideline-Recommended Approach
The Endocrine Society Clinical Practice Guideline 3 recommends a shared decision-making approach with the following principles:
For women WITH a uterus:
- Use the lowest effective dose of estrogen combined with progestin
- Start with lower doses than historical WHI trials
- Titrate upward based on clinical response
- Transdermal preparations are preferable for women with VTE risk, hypertension, hypertriglyceridemia, obesity, metabolic syndrome, diabetes, or gallbladder disease history 3
For women WITHOUT a uterus (post-hysterectomy):
- Estrogen-only therapy is appropriate
- Starting doses typically lower than WHI protocols
- Consider higher starting doses (e.g., transdermal estradiol 100 µg) for younger women with surgical menopause or premature ovarian insufficiency, then taper as tolerated 3
Monitoring Approach
- Do not routinely measure estradiol levels except when symptoms fail to improve with escalating doses, particularly after switching from oral to transdermal administration 3
- Focus on clinical response rather than laboratory values
Common Pitfalls to Avoid
- Compounded "bioidentical" hormones are not safer or more effective than FDA-approved formulations, despite marketing claims
- The term "bioidentical" is misleading—FDA-approved estradiol products are molecularly identical to endogenous hormones
- Compounded preparations lack quality control standardization across pharmacies, even when protocols claim otherwise 2
- Direct-to-consumer marketing of unproven hormone protocols exploits women's concerns about menopause without providing evidence-based risk-benefit information 1
Risk-Benefit Profile of Evidence-Based Hormone Therapy
Based on high-quality evidence from the Women's Health Initiative 4, 5:
Combined estrogen-progestin therapy:
- Reduces fractures (moderate certainty)
- Increases breast cancer risk (moderate certainty)
- Increases stroke and VTE risk (low to moderate certainty)
- Increases gallbladder disease (low certainty) 5
Estrogen-only therapy (post-hysterectomy):
- Reduces fractures (moderate certainty)
- Makes little to no difference in breast cancer risk (moderate certainty)
- Increases stroke risk (moderate certainty)
- Increases gallbladder disease (moderate certainty) 5
The failure to regulate compounding pharmacies has created opportunities for ethical violations in hormone therapy marketing and delivery 1. Clinicians should prescribe only FDA-approved hormone preparations following established clinical practice guidelines 3.